Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Familial Combined Hyperlipidemia

The Biology of FCHL: Beyond Standard Cholesterol Tests

At a Glance

Familial combined hyperlipidemia (FCHL) often causes the body to produce too many cholesterol- and triglyceride-carrying particles, so standard cholesterol tests may miss the full picture. ApoB, non-HDL cholesterol, changing lipid results, and family history help clinicians evaluate the condition.

In Familial Combined Hyperlipidemia (FCHL), an important primary issue is an increased production of Apolipoprotein B (ApoB) [1][2]. Think of ApoB as the structural “suitcase” that carries both cholesterol and triglycerides through your bloodstream. Importantly, each atherogenic particle (like VLDL or LDL) carries exactly one ApoB molecule, so measuring ApoB directly counts the number of these harmful particles [3][4].

Because your body produces an excess of these particles, your blood tests may show a “mixed” result—both high cholesterol and high triglycerides. However, because the liver’s production and your diet vary, one test might show high cholesterol while the next shows high triglycerides, even though the underlying problem of too many ApoB particles remains the same [4][2].

FCHL vs. FH vs. FCS: Three Different Paths

While all three conditions lead to high lipids, they happen for different biological reasons:

  • FCHL: Usually polygenic, meaning it results from the combined effect of many small genetic variations plus metabolic factors like insulin resistance. The main issue involves an overproduction of particles, though clearance issues can also play a role [5][6].
  • FH (Familial Hypercholesterolemia): Typically monogenic (caused by one major pathogenic gene variant like LDLR). In FH, the primary issue is severely reduced clearance—the body cannot clear LDL from the blood properly [7][8].
  • FCS (Familial Chylomicronemia Syndrome): A rare, severe condition where the body lacks the enzyme pathway (LPL) needed to break down fats [9]. This requires biallelic variants (two pathogenic copies) and leads to extreme triglyceride levels and a high risk of pancreatitis [10][11][12][13].

The Role of the LPL Gene

The LPL gene provides instructions for the enzyme that acts like a “cleaver,” chopping up triglycerides so your body can use them for energy [14].

  • In FCS, a person has two pathogenic copies of this gene (or related genes), leading to a severe system failure [12][13].
  • In FCHL, a person might have one slightly less efficient copy of LPL (a heterozygous variant) [15]. This acts as a risk factor that nudges triglycerides higher but does not cause the whole syndrome on its own; many other genes and lifestyle factors must be involved [5][8].

How FCHL is Evaluated

There is no single universally accepted threshold or “FCHL gene test.” Instead, clinicians use an evaluation framework to identify the phenotype [16]. You may be evaluated for FCHL by looking at:

  1. Elevated ApoB and Non-HDL-C: Indicating an excess of atherogenic particles [2][17].
  2. Fluctuating Lipid Profile: A history of labs showing variable levels of cholesterol and triglycerides over time [4].
  3. Family History: A pattern of early heart disease or mixed dyslipidemia in the family [2][5].
  4. Ruling out Secondary Causes: Clinicians ensure your high lipids are not simply caused by uncontrolled diabetes, hypothyroidism, kidney disease, heavy alcohol use, pregnancy, or lipid-raising medications.

Why Standard Tests May Fall Short

Most routine blood panels calculate LDL-C (the “bad” cholesterol) using the Friedewald formula. However, when your triglycerides rise, this formula becomes increasingly imprecise. Calculation error is not the same as underestimating your true cardiovascular risk, but when triglycerides exceed 400 mg/dL, traditional calculations are generally not valid [18][19].

To get a complete picture, specialized markers are used alongside LDL-C:

  • Apolipoprotein B (ApoB): Measures the actual number of particles in your blood [20][21].
  • Non-HDL Cholesterol (Non-HDL-C): Calculated by subtracting your “good” cholesterol (HDL) from your total cholesterol. This includes all the cholesterol content of atherogenic particles and remains reliable when triglycerides are high [22][20].

Your Individualized Checklist

When you review your labs with your doctor, remember that target numbers depend heavily on whether you have established ASCVD, diabetes, or other risk factors. Work with your clinician to define your personal targets for:

  • [ ] Apolipoprotein B (ApoB) (Targets are clinician-set based on risk, sometimes <65–90 mg/dL depending on the guideline) [23].
  • [ ] Non-HDL Cholesterol (Targets are risk-based, often <85–100 mg/dL for higher risk patients) [23][22].
  • [ ] Direct LDL Measurement or Validated Equation (If triglycerides are elevated) [18].
  • [ ] Fasting Glucose or HbA1c (To check for underlying metabolic factors) [6].

Common questions in this guide

What is the main problem in familial combined hyperlipidemia?
FCHL often causes the body to make too many ApoB-containing particles, which carry cholesterol and triglycerides through the blood. Because particle production and metabolic factors can vary, cholesterol and triglyceride results may be high at different times.
Why can an ApoB test add information beyond my cholesterol result?
Each particle that can contribute to artery disease carries one ApoB molecule, so an ApoB test estimates the number of these particles rather than only the cholesterol inside them. This can show a high particle burden when LDL-C or total cholesterol does not show the full picture.
How is FCHL different from familial hypercholesterolemia and familial chylomicronemia syndrome?
FCHL is usually influenced by many genes and metabolic factors and often involves making too many particles. Familial hypercholesterolemia usually results from a major gene change that reduces removal of LDL from the blood. Familial chylomicronemia syndrome is much rarer and occurs when both copies of an LPL-pathway gene are affected, causing extremely high triglycerides and a high risk of pancreatitis.
Can a genetic test confirm familial combined hyperlipidemia?
There is no single universally accepted FCHL gene test or cutoff that confirms the condition. Clinicians usually consider ApoB and non-HDL cholesterol, changing lipid results, family history, and whether other causes such as diabetes, thyroid disease, kidney disease, alcohol use, pregnancy, or medications have been excluded.
Which tests may help evaluate FCHL when triglycerides are high?
ApoB and non-HDL cholesterol can help estimate the burden of cholesterol-carrying particles when triglycerides vary or are high. When triglycerides exceed 400 mg/dL, traditional calculated LDL-C is generally not valid, so a direct LDL measurement or validated equation may be considered. Your clinician may also check fasting glucose or HbA1c for metabolic factors.
How are ApoB and non-HDL cholesterol targets chosen?
Targets are based on your overall cardiovascular risk, including established atherosclerotic cardiovascular disease, diabetes, and other risk factors. Ask your clinician which targets and which measure should be followed over time, especially if your triglycerides fluctuate.

Get notified when new evidence is published on hyperlipidemia, familial combined, LPL related.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (23)
  1. 1

    Familial combined hyperlipidemia: An overview of the underlying molecular mechanisms and therapeutic strategies.

    Taghizadeh E, Esfehani RJ, Sahebkar A, et al.

    IUBMB life 2019; (71(9)):1221-1229 doi:10.1002/iub.2073.

    PMID: 31271707
  2. 2

    [Familial combined hyperlipidemia - the most common genetic dyslipidemia in population and in patients with premature atherothrombotic cardiovascular disease].

    Vaverková H, Karásek D

    Vnitrni lekarstvi 2018; (64(1)):25-29.

    PMID: 29498872
  3. 3

    Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A review.

    Taghizadeh E, Mardani R, Rostami D, et al.

    Journal of cellular biochemistry 2019; (120(6)):8891-8898 doi:10.1002/jcb.28311.

    PMID: 30556165
  4. 4

    FAMILIAL COMBINED HYPERLIPIDEMIA: CURRENT KNOWLEDGE, PERSPECTIVES, AND CONTROVERSIES.

    Bello-Chavolla OY, Kuri-García A, Ríos-Ríos M, et al.

    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2018; (70(5)):224-236 doi:10.24875/RIC.18002575.

    PMID: 30307446
  5. 5

    Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia.

    Trinder M, Vikulova D, Pimstone S, et al.

    Atherosclerosis 2022; (340()):35-43 doi:10.1016/j.atherosclerosis.2021.11.032.

    PMID: 34906840
  6. 6

    Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight.

    Baila-Rueda L, Cenarro A, Lamiquiz-Moneo I, et al.

    The Journal of nutritional biochemistry 2018; (53()):48-57 doi:10.1016/j.jnutbio.2017.10.005.

    PMID: 29190549
  7. 7

    [Congenital disorders of lipoprotein metabolism].

    März W, Grammer TB, Delgado G, Kleber ME

    Herz 2017; (42(5)):449-458 doi:10.1007/s00059-017-4578-x.

    PMID: 28555288
  8. 8

    Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): a reappraisal by using a resequencing approach.

    Minicocci I, Prisco C, Montali A, et al.

    Atherosclerosis 2015; (242(2)):618-24.

    PMID: 26342331
  9. 9

    Genetics of Hypertriglyceridemia.

    Dron JS, Hegele RA

    Frontiers in endocrinology 2020; (11()):455 doi:10.3389/fendo.2020.00455.

    PMID: 32793115
  10. 10

    Hypertriglyceridaemia: an update.

    Wierzbicki AS, Kim EJ, Esan O, Ramachandran R

    Journal of clinical pathology 2022; (75(12)):798-806 doi:10.1136/jclinpath-2021-207719.

    PMID: 35710321
  11. 11

    Recognition and management of persistent chylomicronemia: A Joint Expert Clinical Consensus by the National Lipid Association and the American Society for Preventive Cardiology.

    Saadatagah S, Larouche M, Naderian M, et al.

    Journal of clinical lipidology 2025; (19(4)):723-736 doi:10.1016/j.jacl.2025.03.012.

    PMID: 40360374
  12. 12

    Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association.

    Javed F, Hegele RA, Garg A, et al.

    Journal of clinical lipidology 2025; (19(3)):382-403 doi:10.1016/j.jacl.2025.03.013.

    PMID: 40234111
  13. 13

    Incidental finding of severe hypertriglyceridemia in children. Role of multiple rare variants in genes affecting plasma triglyceride.

    Buonuomo PS, Rabacchi C, Macchiaiolo M, et al.

    Journal of clinical lipidology 2017; (11(6)):1329-1337.e3 doi:10.1016/j.jacl.2017.08.017.

    PMID: 28951076
  14. 14

    Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis.

    Chyzhyk V, Brown AS

    Trends in cardiovascular medicine 2020; (30(2)):80-85 doi:10.1016/j.tcm.2019.03.001.

    PMID: 31003756
  15. 15

    The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants.

    Perera SD, Wang J, McIntyre AD, et al.

    Journal of clinical lipidology 2023; (17(1)):87-93 doi:10.1016/j.jacl.2022.11.007.

    PMID: 36476373
  16. 16

    Familial combined hyperlipidemia is a polygenic trait.

    Gill PK, Hegele RA

    Current opinion in lipidology 2022; (33(2)):126-132 doi:10.1097/MOL.0000000000000796.

    PMID: 34690300
  17. 17

    Familial Hypercholesterolemia, Familial Combined Hyperlipidemia, and Elevated Lipoprotein(a) in Patients With Premature Coronary Artery Disease.

    Vikulova DN, Trinder M, Mancini GBJ, et al.

    The Canadian journal of cardiology 2021; (37(11)):1733-1742 doi:10.1016/j.cjca.2021.08.012.

    PMID: 34455025
  18. 18

    Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.

    Wilson PWF, Jacobson TA, Martin SS, et al.

    Journal of clinical lipidology 2021; (15(5)):629-648 doi:10.1016/j.jacl.2021.09.046.

    PMID: 34802986
  19. 19

    Comparison of the accuracy of the Friedewald, Martin, and Sampson formulas to estimate very low levels of low-density lipoprotein cholesterol.

    Benido Silva V, Chaves C, Oliveira JC, Palma I

    Endokrynologia Polska 2023; (74(2)):203-210 doi:10.5603/EP.a2023.0025.

    PMID: 37155302
  20. 20

    Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association.

    Soffer DE, Marston NA, Maki KC, et al.

    Journal of clinical lipidology 2024; (18(5)):e647-e663 doi:10.1016/j.jacl.2024.08.013.

    PMID: 39256087
  21. 21

    Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.

    Carr SS, Hooper AJ, Sullivan DR, Burnett JR

    Pathology 2019; (51(2)):148-154 doi:10.1016/j.pathol.2018.11.006.

    PMID: 30595507
  22. 22

    Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

    Langlois MR, Chapman MJ, Cobbaert C, et al.

    Clinical chemistry 2018; (64(7)):1006-1033 doi:10.1373/clinchem.2018.287037.

    PMID: 29760220
  23. 23

    Top 10 Concepts in Secondary ASCVD Prevention From the 2026 ACC/AHA Dyslipidemia Guideline: What Is New and Why It Matters.

    Siddiqi AK, Jacob J, Khan MS, Kulkarni A

    Current atherosclerosis reports 2026; (28(1)).

    PMID: 42709273

This page explains FCHL biology and lipid testing for educational purposes and does not replace medical advice. Ask your clinician to interpret your ApoB, non-HDL-C, triglyceride, and LDL-C results in the context of your cardiovascular risk.

Guide contents hyperlipidemia, familial combined, LPL related
Research & Literature
01 Understanding Your Diagnosis 03 Cardiovascular Risks and Metabolic Health in FCHL